Tryton begins trial of side branch stent
This article was originally published in Clinica
Executive Summary
Tryton Medical, of Durham, North Carolina, has initiated a registry study of its Tryton side branch stent. Called E-Tryton 150, the study is one of four registries in Europe evaluating the Tryton device in real-world clinical settings. It will enrol 150 patients with a primary endpoint of overall rate of major adverse cardiac events (MACE) – defined as cardiac death, myocardial infarction and target lesion revascularisation (main and/or side branch) – at six months following the procedure. The study will also assess the technical and procedural success of the stent. Designed to treat bifurcated atherosclerotic lesions, the cobalt chromium Tryton side branch stent is used in conjunction with a conventional drug-eluting stent. It was CE marked in February 2008.
You may also be interested in...
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.